Evidence of type II pneumocyte apoptosis in the pathogenesis of idiopathic pulmonary fibrosis (IPF)/usual interstitial pneumonia (UIP)

J V Barbas-Filho, M A Ferreira, A Sesso, R A Kairalla, C R R Carvalho, V L Capelozzi

Abstract
Background/Aims—The pathogenesis of idiopathic pulmonary fibrosis (IPF)/usual interstitial pneumonia (UIP), a chronic and incurable human respiratory disease, is not well established. This study was designed to investigate whether the apoptosis of type II pneumocytes could be the precipitating factor in the pathogenesis of IPF.

Methods—Nineteen specimens obtained by retrospective review of the medical and pathological records of 55 patients with IPF, four normal subjects, and 10 disease control lungs were analysed. The selected specimens had normal alveoli with intervening patchy scarring of the lung parenchyma, fulfilling the pathological criteria for UIP. To identify individual cells undergoing apoptosis in the normal alveoli, electron microscopy and in situ end labeling of fragmented DNA were performed on paraffin wax embedded sections using digoxigenin-11-dUTP and the enzyme terminal deoxynucleotidyl transferase.

Results—Apoptosis was detected in the normal alveoli of 17 of the 19 patients with IPF/UIP and was absent in the controls. Electron microscopy demonstrated apoptotic changes in type II pneumocytes. These results indicate that apoptotic type II pneumocyte death occurs in normal alveoli of IPF/UIP and could be the principal cause of several events that account for the histological, clinical, and functional alterations seen in IPF/UIP.

Conclusions—In conclusion, numerous type II pneumocytes from the normal alveoli of most patients with IPF/UIP actively undergo programmed cell death. This finding may shed new light on the pathogenesis of this disease, with implications mainly for the treatment of affected patients.

(J Clin Pathol 2001;54:132–138)

Keywords: apoptosis; type II pneumocytes; idiopathic pulmonary fibrosis; pathogenesis
In this study, we investigate the hypothesis that apoptosis of type II pneumocytes could be the first and leading cause of several events that result in IFP/UIP.

Methods

STUDY POPULATION

The study population was identified by retrospective review of the medical and pathological records of 55 patients with IPF at the “Hospital das Clínicas” from 1985 to 1998. In all subjects, lung tissue was obtained by open lung biopsy from two different sites, most often the upper and lower lobes of the same lung. All subjects were evaluated clinically, radiographically, and by lung function tests. All diagnoses were established according to previously described clinical and histological criteria.

MORPHOLOGICAL STUDY

The tissue specimens were immediately fixed in 10% neutral buffered formalin and embedded in paraffin wax. Six sections (6 µm thick) from each paraffin wax block were stained routinely with haematoxylin and eosin. The slides were examined using light microscopy and classified as UIP according to the previously defined criteria. Because our working hypothesis was that apoptosis in the normal alveoli can precede end stage scarring, only the cases with extensive normal alveolar areas were included in our study. Thus, 19 patients (15 men and four women; mean age, 59 years) with IPF, pathologically classified as UIP, were selected because of the presence of normal or nearly normal alveoli with intervening patchy scarring of the lung parenchyma (fig 1A). Patients with connective tissue disease (a common cause of UIP), drug or chemical exposure, or other possible aetiologies of interstitial lung disease, such as bronchiolitis obliterans and diffuse alveolar damage, lymphocytic interstitial pneumonia, bronchiolitis obliterans, and organising pneumonia, or unclassifiable forms of chronic interstitial pneumonia were excluded from our study. Normal control lungs were from four subjects (three men and one woman; mean age, 41 years) who were victims of sudden traumatic death (two accidents, one homicide, and one suicide). To ensure that lungs were collected with minimal autolytic changes, we selected victims whose necropsy was performed within the first six hours after death. Ten patients (three women and seven men; mean age, 60 years; SD, 3.6) who had undergone resection for lung cancer were included as disease controls. Tissue specimens were obtained from areas without pneumonia, tumour, or emphysema. None of these control subjects met any of the histology criteria for pulmonary fibrosis.

Electron microscopy was performed on samples from two patients (a man and woman; 59 and 65 years old, respectively) who died from pulmonary fibrosis and whose biopsies were included in our study. Tissues were fixed in 2% buffered glutaraldehyde, embedded in Araldite, and thin sections were stained with uranyl acetate and lead citrate.

IN SITU DETECTION AND MEASUREMENT OF APOPTOTIC CELLS

For the in situ detection of apoptosis at the level of a single cell we used the deoxynucleotidyl transferase (TdT) method of end labelling (Boehringer Mannheim, Mannheim, Germany). This method involves the addition of deoxyuridine triphosphate (dUTP) labelled with fluorescein to the ends of the DNA fragments by the catalytic action of TdT. All the end labelling experiments were performed several times so that the results for various tissue samples, including rat prostate, could be standardised. Paraffin wax embedded sections (4–6 µm) were layered on to glass slides. The tissue sections were dewaxed with xylene and rehydrated with graded dilutions of ethanol in water. The slides were washed four times with double distilled water for two minutes and immersed in TdT buffer (Boehringer Mannheim). The sections were then covered with TdT (0.3 U/µl) and fluorescein labelled dUTP in TdT buffer, and the samples were incubated in a humid atmosphere at 37°C for 60 minutes.
For negative controls, TdT was eliminated from the reaction mixture. The sections were then incubated with antibody specific for fluorescein conjugated to peroxidase. The stains were visualised with a substrate system in which nuclei with DNA fragmentation stained brown. The reaction was terminated by washing the sections twice in phosphate buffered saline. The nuclei without DNA fragmentation stained blue as a result of counterstaining with haematoxylin. Positive controls consisted of rat prostate gland after castration. Two sections from each specimen were examined. Quantitation was performed by a conventional point counting procedure, using a reticulated eyepiece (100 points and 50 lines). At a magnification of ×100, 10 non-coincident microscopic fields were studied for each sample to estimate the proportion of the section occupied by apoptotic cells in normal and remodelled tissue; a total of 1000 points, covering an area of 1.0 mm²/section, were counted. The error of this procedure was estimated according to Gundersen and colleagues and was always less than 5%. After this procedure, the number of points overlying apoptotic nuclei in positive areas of normal and remodelled lung were counted in 10 fields of ×400 magnification, covering an area of 62 500 µm²/field for each sample. This represented the proportion of positive apoptotic nuclei in areas of normal and remodelled tissue. The extension of areas with apoptotic nuclei (Aapop) and proportion of apoptotic nuclei in positive areas (Papop) were obtained by the following relations:

\[
A_{\text{apop}} = \frac{P_{\text{apop}}}{P_{\text{tiss}}} = (\% \text{ section})
\]

\[
P_{\text{apop}} = \frac{P_{\text{Napop}}}{P_{\text{tiss}}} = (\%)
\]

where \(P_{\text{tiss}}\), \(P_{\text{apop}}\), and \(P_{\text{Napop}}\) were the number of points overlying tissue with apoptotic nuclei, total tissue (normal or remodelled), and apoptotic nuclei, respectively (as a percentage).

For all morphometric procedures, an estimate of the error (CE) was computed by the following relations:

\[
CE = \frac{SE}{\text{mean}}
\]

where \(SE\) represents the standard error of the mean. Because of the number of points counted, CE was kept under 10% in all morphometric measurements.

**STATISTICAL ANALYSIS**

Comparisons between the extent of apoptosis in normal alveoli and remodelled areas and the percentage of apoptotic type II pneumocyte nuclei in these areas in lung sections from patients with IPF/UIP were made with a paired samples \(t\) test using the SPSS program, version 6.0.

**Results**

In situ end labelling of fragmented DNA with terminal deoxynucleotidyl transferase and digoxigenin-11-dUTP did not reveal apoptosis in sections from the four normal and 10 disease control lungs (fig 2A). In the prostatic epithelium of four day castrated rats, used as positive controls, only the apoptotic cells and the apoptotic bodies within the macrophages at the base of the epithelium reacted positively. Sections of lung from 17 of the 19 patients with UIP showed numerous cells with genomic DNA fragments in their nuclei (fig 2B). Under a light microscope at high magnification most of these cells appeared to be type II pneumocytes because they were well shaped, rounded, and had eosinophilic cytoplasm (fig 1B). Apoptotic type II pneumocytes were frequently found in regions of lung with intervening normal or nearly normal alveoli. They were found in small numbers in remodelled regions replaced by fibrous tissue. Both the extent of the regions with apoptotic cells and the number of apoptotic nuclei varied among the patients (table 1). There was a significant difference (\(p = 0.0001\)) between the proportion of regions with apoptotic cells and the number of apoptotic nuclei available from
Table 1: Quantitative analysis data and comparison between the extent of apoptosis in normal alveoli and remodelled areas and the proportion of apoptotic type II pneumocyte nuclei in these areas in sections of lung from patients with IPF/UIP

<table>
<thead>
<tr>
<th>Patient</th>
<th>Normal Extent of areas with apoptotic nuclei of section (%)</th>
<th>Proportion of apoptotic nuclei in normal areas of section (%)</th>
<th>Remodelling Extent of areas with apoptotic nuclei of section (%)</th>
<th>Proportion of apoptotic nuclei in normal areas of section (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>15.3</td>
<td>5.0</td>
<td>14.0</td>
<td>3.0</td>
</tr>
<tr>
<td>2</td>
<td>20.0</td>
<td>2.03</td>
<td>19.0</td>
<td>3.0</td>
</tr>
<tr>
<td>3</td>
<td>50.0</td>
<td>7.08</td>
<td>30.0</td>
<td>2.0</td>
</tr>
<tr>
<td>4</td>
<td>45.0</td>
<td>4.8</td>
<td>18.0</td>
<td>1.9</td>
</tr>
<tr>
<td>5</td>
<td>10.0</td>
<td>0.0</td>
<td>29.0</td>
<td>0.0</td>
</tr>
<tr>
<td>6</td>
<td>15.0</td>
<td>3.8</td>
<td>20.0</td>
<td>2.9</td>
</tr>
<tr>
<td>7</td>
<td>25.0</td>
<td>5.0</td>
<td>35.0</td>
<td>3.4</td>
</tr>
<tr>
<td>8</td>
<td>50.0</td>
<td>6.6</td>
<td>28.0</td>
<td>2.0</td>
</tr>
<tr>
<td>9</td>
<td>30.0</td>
<td>9.0</td>
<td>23.0</td>
<td>5.0</td>
</tr>
<tr>
<td>10</td>
<td>10.0</td>
<td>0.0</td>
<td>18.0</td>
<td>0.0</td>
</tr>
<tr>
<td>11</td>
<td>50.0</td>
<td>11.0</td>
<td>35.0</td>
<td>8.7</td>
</tr>
<tr>
<td>12</td>
<td>50.0</td>
<td>12.0</td>
<td>32.0</td>
<td>6.7</td>
</tr>
<tr>
<td>13</td>
<td>10.0</td>
<td>1.9</td>
<td>18.0</td>
<td>2.0</td>
</tr>
<tr>
<td>14</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td>15</td>
<td>45.0</td>
<td>9.0</td>
<td>30.0</td>
<td>5.7</td>
</tr>
<tr>
<td>16</td>
<td>50.0</td>
<td>13.0</td>
<td>30.0</td>
<td>8.9</td>
</tr>
<tr>
<td>17</td>
<td>50.0</td>
<td>6.6</td>
<td>28.0</td>
<td>5.4</td>
</tr>
<tr>
<td>18</td>
<td>25.1</td>
<td>3.5</td>
<td>32.0</td>
<td>7.6</td>
</tr>
<tr>
<td>19</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
</tr>
</tbody>
</table>

Patients (total) 19
Mean (SEM) 28.9 (4.3) 5.4 (0.9) 24.1 (2.0) 3.3 (0.6)
CV between groups 33.6 37.7 36.0 40.2
CV within groups 30.1 24.0 26.1 18.2
P Value 0.0001 0.0001

CV, coefficient of variation; IPF, idiopathic pulmonary fibrosis; UIP, usual interstitial pneumonia.

Discussion
We report the occurrence of apoptotic alveolar cell death in IPF. Uhal and colleagues1 suggested that apoptosis might be a mechanism of cell death in fibrosing lung disease. Since then, there has been a rapidly growing and relevant literature on apoptosis in acute lung injury and experimental models of lung fibrosis have been developed.5

In our study, apoptosis was identified by in situ end labelling of fragmented DNA with TdT and digoxigenin-11-dUTP, a commonly accepted method for the detection of the apoptotic process.18 19 There has been concern about the ability of such in situ labelling methods to distinguish between cell necrosis and apoptosis. However, in our study the detection of a positive reaction with in situ end labelling was correlated with the presence of typical signs of apoptosis (masses of chromatin and well preserved apoptotic bodies) in sections stained with haematoxylin and eosin.13 Moreover, the absence of an inflammatory reaction in regions of lung with intervening normal or nearly normal alveoli in most of our patients argues against necrosis and for apoptosis. Furthermore, no positive staining was detected in alveolar cells from age matched normal subjects whose lungs were processed in the same manner as those of our patients, and the in situ end labelling of fragmented DNA was not detected when the enzyme TdT was omitted.

We found that numerous cells in the normal alveoli of patients with idiopathic pulmonary fibrosis underwent apoptosis (fig 1B and fig 2B). Most of these cells were morphologically similar to type II pneumocyte cells under high power magnification. Further evidence of apoptotic changes in type II pneumocytes was gained by electron microscopy (fig 3A–C). Clumping of chromatin at the inner nuclear membrane is a hallmark of apoptosis. The evaluation of nuclear alterations by electron microscopy is thought to be the best way of detecting programmed cell death.1 An early stage of explicit apoptosis is the disassembly of the nuclear lamina, a scaffold where the euchromatin loops anchor. Consequently, these loops collapse and there is a progressive increase in the amount of condensed perinuclear chromatin and a corresponding decrease in the density of euchromatin normally represented by a delicate texture of granule filamentous material. This clarification of a sector of the apoptotic nuclei progresses to the point where this region looses most of its electron density, eventually becoming translucent. These changes can be seen in many of the figures of Kerr and colleagues, and also in other electron microscopic images of advanced, non-fragmented, apoptotic nuclei. One of the reasons that not all apoptotic nuclei have a translucent euchromatic region is that during explicit apoptosis the nucleus tends to shrink, thereby concentrating the contents of its various parts. However, as far as we know, clarification of the nuclear content (as seen in the dead cell in fig 3C) has not been ascribed to necrosis.1

www.jclinpah.com
The remodelled areas had few or no apoptotic cells, whereas apoptotic nuclei were frequently seen in areas with little involvement. This finding suggests that the loss of type II pneumocytes through apoptosis is a primary process that precedes the filling of acellular space by fibrous tissue in the absence of an inflammatory reaction. The extent and the number of apoptotic type II pneumocytes varied among the patients (table 1). The absence of apoptosis in two of our patients is intriguing. The clinical and histological features of these patients were similar to those of the others, but perhaps their disease was in remission.

The triggering factors for apoptotic type II pneumocytes in IPF/UIP remain to be elucidated. Fas ligand was detected in inflammatory cells in bronchoalveolar lavage fluid (BALF) from patients with IPF. In addition, the expression of Fas appeared to be upregulated in bronchiolar and alveolar cells. However, in...
Apoptosis in IFP/UIP

that study there was no indication of the alveolar epithelial cell type expressing Fas. This mechanism appears not to be involved in our cases because the alveoli with apoptotic cells do not contain inflammatory cells.

We predicted that excessive apoptosis might cause damage to type II pneumocytes, as deduced from nuclear changes and signs of cytoplasmic degeneration (figs 2B and 3A–C). This finding leads us to hypothesise that type II cell apoptosis plays an important pathological role as an early lesion in IPF, raising important questions about the mechanisms involved in the pathogenesis and clinical correlation of the disease.

First of all, the impact of apoptosis on the surfactant system could have several consequences on alveolar histoarchitecture. These apoptotic features could be the morphological expression of impaired release and/or defective surfactant production, with quantitative and qualitative alterations in the surfactant system. This abnormal or absent surfactant leads to alveolar collapse, alveolar wall apposition, and compensatory alveolar duct enlargement—the alveolar ducts do not collapse because of the interdependence between adjacent units. The surfactant system abnormalities that occur with IPF have strong support from the literature. Robinson and co-workers studied 15 untreated patients with IPF diagnosed by open lung biopsy and found less than half the amount of phospholipid in BALF from these patients compared with healthy volunteers. In addition, patients with IPF had a lower proportion of phosphatidyl glycerol and a higher proportion of phosphatidyl inositol in the BALF than did healthy volunteers. The authors correlated pronounced changes in phospholipid composition with more advanced fibrotic processes in the histopathology of the disease. In another report, Mc Cormac and co-workers measured surfactant protein A (SP-A) in BALF from 44 patients with IPF and 33 healthy volunteers. The mean SP-A/total phospholipids (PL) was lower in patients with IPF than in healthy volunteers. They concluded that SP-A/PL is a biochemical marker in BALF that might predict survival in patients with IPF/UIP.

The implications of alveolar collapse in the pathogenesis of IPF/UIP have been emphasised by Burkhardt, Katzenstein, and Myers. In addition, alveolar collapse, more so than fibrosis, explains the findings of Conson and et al. These authors quantified lung structure in IPF by computerised tomography and histological analysis. The results showed that in contrast to control lungs IPF was associated with a reduction in airspace volume, without changes in tissue volume or weight. Lung surface area decreased two thirds and mean parenchymal thickness increased 10-fold. They concluded that the architectural rearrangement of lung tissue in IPF lungs contributed to the loss of airspace and surface area without increasing total lung tissue. Reinforcing this concept, the collagen content and morphological degree of fibrosis were quantified in nine patients with IPF and in six control subjects by Fulmer and et al. They found no significant difference in collagen content among IPF and control lungs. Equally, there was no correlation between the morphological assessment of the degree of fibrosis and collagen content. The results of this study are consistent with the concept that IPF is a disease involving alterations in quality, form, and location of collagen, rather than simply a disease of increased interstitial collagen. Furthermore, recent evidence has shown that the absence of prostaglandin E, usually produced by type II alveolar cells, enhances fibroblast growth and collagen synthesis. Nevertheless, delayed repair of the alveolar epithelium disturbs normal epithelial–fibroblast interactions and is sufficient to promote the fibroblastic process. The “fibroblast foci” described by Katzenstein and Myers must correspond to the fibrosis, which appears in the denuded areas of alveolar membrane resulting from type II pneumocyte apoptosis. Another consequence of type II pneumocyte apoptosis might be related to the turnover of type I pneumocytes. Because type I pneumocytes are produced by the proliferation and transformation of type II pneumocytes, the progressive depletion of the latter leads to a proportional reduction in the number of type I pneumocytes.

The missing type I pneumocytes in the alveolar duct and respiratory bronchiolo are replaced by the proliferation of cuboidal epithelial cells derived from bronchiolo basal cells (type A cuboidal cells) and from cuboidal cells from the respiratory bronchiolo (type B cuboidal cells), resulting in a honeycomb configuration. Thus, if type II pneumocyte apoptosis is the pathogenic mechanism involved in IPF, it is difficult to understand the hypertrophy and hyperplasia of these cells to renew the alveolar surface, as reported by Kawanami and et al. On the other hand, it is currently accepted that type II pneumocyte proliferation and transformation occur after type I pneumocyte necrosis, as in acute interstitial pneumonia. In the latter, the histological hallmark is interstitial fibrosis and oedema associated with type II pneumocyte hyperplasia. Furthermore, in non-specific interstitial pneumonia/fibrosis type II pneumocyte hyperplasia occurs in 50% and 44% of the cases, respectively. It may be that the patients in Kawanami’s report with hypertrophy and hyperplasia of type II pneumocytes in “areas of less severe degree of fibrosis” have non-specific interstitial pneumonia/fibrosis, as recently described by Katzenstein and colleagues, and now included in the new IPF classification. Thus, based on the above considerations, we think that the presence of type II pneumocyte hyperplasia in lung biopsy specimens exhibiting an interstitial process should suggest a diagnosis other than UIP.

Because type II pneumocyte apoptosis might be involved in IPF/UIP pathogenesis, it is reasonable to suppose that the presence of alveolitis is not a necessary prelude to IPF. As previously emphasised by Carrington et al., we must be careful in accepting the concept...
proposed by Tubbs et al., who described desquamative interstitial pneumonia (DIP) as the initial or cellular phase of IIP. This finding has been confirmed in the recent report of Hartman et al. They studied radiological progression in treated patients with UIP and DIP and found that these two entities have different radiological behaviour. According to Katzenstein et al., in UIP “the inflammation occurs mainly in areas of collagen deposition or honeycomb change, and rarely in otherwise unaltered alveolar septa. There is no evidence that inflammation is more prominent in early disease. The presence of severe inflammation, in fact, should suggest a diagnosis other than UIP.”

Finally, we must emphasise that UIP progresses by recurrent episodes of type II apoptosis in new pulmonary parenchymal areas. This observation is derived from the concomitant presence of fibrotic areas and normal alveoli where the process starts by type II pneumocyte apoptosis.

In conclusion, we found that numerous type II pneumocytes from the normal alveoli of most patients with IPF/UIP actively undergo programmed cell death. This finding sheds new light on the pathogenesis of this disease, which might have important implications for patient treatment. In the future, steroid treatment, which is successful in less than 20% of patients with IPF/UIP, should be replaced by substances with inhibitory action in type II pneumocyte apoptosis.

We are indebted to the scientific department of FMUSP for the helpful preparation of the photomicrographs. This work was supported by the Brazilian funding agencies: FAPESP, CAPES, CNPq, and LIM-HCFMUSP.

Evidence of type II pneumocyte apoptosis in the pathogenesis of idiopathic pulmonary fibrosis (IPF)/usual interstitial pneumonia (UIP)

J V Barbas-Filho, M A Ferreira, A Sesso, R A Kairalla, C R R Carvalho and V L Capelozzi

doi: 10.1136/jcp.54.2.132

Updated information and services can be found at: http://jcp.bmj.com/content/54/2/132

These include:

References
This article cites 39 articles, 4 of which you can access for free at: http://jcp.bmj.com/content/54/2/132#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Interstitial lung disease (25)

Notes

To request permissions go to: http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to: http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to: http://group.bmj.com/subscribe/